Emerging Therapies and Diagnostic Advances in Cutaneous Lupus and Dermatomyositis

Conclusions

• Cutaneous lupus and dermatomyositis are increasingly treatable diseases, but accurate diagnosis remains essential because both are often misclassified and require tailored evaluation.
• Smoking cessation, sun protection, and stopping drug triggers remain important foundations of care for cutaneous lupus, especially for refractory or drug-induced disease.
• Hydroxychloroquine remains first-line therapy for cutaneous lupus, but many patients require escalation to immunosuppressives or newer biologic and targeted agents.
• Interferon signaling appears to be a major pathogenic driver in cutaneous lupus, making interferon-pathway inhibition a particularly promising therapeutic strategy.
• Anifrolumab shows the clearest and fastest biologic benefit for cutaneous lupus among the newer agents and is especially effective for skin manifestations.
• Plasmacytoid dendritic cell–targeted therapies such as litifilimab and ILT7-directed approaches can meaningfully improve refractory cutaneous lupus by reducing interferon activity.
• TYK2/JAK-pathway inhibitors and TLR7/8-directed therapies are emerging as effective options for cutaneous lupus, with several late-stage trials showing encouraging skin responses.
• Current cutaneous lupus guidelines still rely heavily on hydroxychloroquine, topical therapies, and stepwise escalation because comparative trials between agents are limited.
• Dermatomyositis should now be recognized as including amyopathic skin-only disease, and updated classification criteria improve identification of these patients.
• Dermatomyositis is frequently mistaken for lupus, so clinicians should look closely for classic skin findings, nailfold changes, muscle involvement, lung disease, and associated malignancy.
• Malignancy screening is an important part of dermatomyositis workup, especially in older patients and those with high-risk features such as specific autoantibodies or severe disease.
• Immunostimulatory herbal supplements may worsen dermatomyositis and should be actively queried and avoided in susceptible patients.
• IVIG remains an important established treatment for dermatomyositis, but access and payer coverage can be harder for skin-predominant disease because the approval data came from muscle studies.
• New dermatomyositis therapies targeting interferon signaling, TYK2/JAK1, FcRn, and B cells are producing promising skin and muscle responses in clinical trials.
• Overall, the presentation concludes that the field is entering a true therapeutic expansion, with multiple targeted treatments now moving from mechanistic rationale to clinically meaningful benefit in both CLE and dermatomyositis.